Skip to content
Beacon

XBIXCorgi U.S. Biotech 2x Daily ETF

Seeks daily investment results that correlate to 2x the daily performance of the SPDR S&P Biotech ETF.

Annual Cost

Fund Size

Return (1Y)Goal

N/A

Track Record

Classification

How Beacon categorizes this fund

Asset class

Alternative

Strategy

Leveraged

Index tracked

S&P Biotechnology Select Industry Index.

Where to buy

Listing

Exchange
Cboe BZX

Full fund details

Objective
Seeks daily investment results that correlate to 2x the daily performance of the SPDR S&P Biotech ETF.
Strategy
Actively managed ETF seeking daily investment results that correlate to 2x the daily performance of the SPDR S&P Biotech ETF. Primarily obtains exposure through derivatives, including total return swaps and equity futures, rebalancing daily to maintain 2x exposure. Invests at least 80% of net assets in financial instruments providing leveraged exposure to U.S. biotechnology companies. The Underlying ETF seeks to track the S&P Biotechnology Select Industry Index, which comprises stocks classified in the GICS Biotechnology sub-industry.

Our take

Structural notes on how this fund behaves. Read our guide on the 6 warning signs.

Leveraged
Warning

Leveraged ETF — not a long-term hold

This fund uses leverage to amplify daily returns (e.g. 2x or 3x of an index). Daily rebalancing creates volatility decay — over weeks and months, the fund's return drifts from the stated multiple. In trending markets with low realised volatility, leveraged index ETFs can outperform their nominal multiple; in sideways or volatile markets they bleed. Designed for short-term tactical use, not buy-and-hold.

Source: Cheng & Madhavan, 'The Dynamics of Leveraged and Inverse ETFs' (2009)

Why we flagged this: strategy=leveraged + leveraged_name_or_strategy

Educational analysis of structural product characteristics. Not investment advice. Always read the fund prospectus and consult a qualified advisor before investing. More

What's next?

You've reviewed XBIX. Save it to your watchlist to track it alongside the other funds you're weighing.

Data updated on 2026-06-06